Prefabrication  ||| S:0 E:15 ||| NNP
of  ||| S:15 E:18 ||| IN
vascularized  ||| S:18 E:31 ||| JJ
bone  ||| S:31 E:36 ||| NN
grafts  ||| S:36 E:43 ||| VBZ
using  ||| S:43 E:49 ||| VBG
a  ||| S:49 E:51 ||| DT
combination  ||| S:51 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
bone  ||| S:66 E:71 ||| NN
marrow  ||| S:71 E:78 ||| NN
mesenchymal  ||| S:78 E:90 ||| NNS
stem  ||| S:90 E:95 ||| VBP
cells  ||| S:95 E:101 ||| NNS
and  ||| S:101 E:105 ||| CC
vascular  ||| S:105 E:114 ||| JJ
bundles  ||| S:114 E:122 ||| NNS
with  ||| S:122 E:127 ||| IN
β-tricalcium  ||| S:127 E:140 ||| JJ
phosphate  ||| S:140 E:150 ||| JJ
ceramics  ||| S:150 E:159 ||| NNS
Large  ||| S:159 E:165 ||| JJ
bone  ||| S:165 E:170 ||| NN
defects  ||| S:170 E:178 ||| NNS
are  ||| S:178 E:182 ||| VBP
often  ||| S:182 E:188 ||| RB
treated  ||| S:188 E:196 ||| VBN
with  ||| S:196 E:201 ||| IN
autologous  ||| S:201 E:212 ||| FW
vascularized  ||| S:212 E:225 ||| FW
bone  ||| S:225 E:230 ||| FW
grafts ||| S:230 E:236 ||| FW
.  ||| S:236 E:238 ||| .
These  ||| S:238 E:244 ||| DT
operations  ||| S:244 E:255 ||| NNS
may  ||| S:255 E:259 ||| MD
be  ||| S:259 E:262 ||| VB
associated  ||| S:262 E:273 ||| VBN
with  ||| S:273 E:278 ||| IN
donor  ||| S:278 E:284 ||| JJ
site  ||| S:284 E:289 ||| NN
morbidities  ||| S:289 E:301 ||| NNS
and  ||| S:301 E:305 ||| CC
a  ||| S:305 E:307 ||| DT
limited  ||| S:307 E:315 ||| JJ
volume  ||| S:315 E:322 ||| NN
of  ||| S:322 E:325 ||| IN
harvested  ||| S:325 E:335 ||| JJ
bone ||| S:335 E:339 ||| NN
.  ||| S:339 E:341 ||| .
To  ||| S:341 E:344 ||| TO
overcome  ||| S:344 E:353 ||| VB
such  ||| S:353 E:358 ||| JJ
issues ||| S:358 E:364 ||| NNS
,  ||| S:364 E:366 ||| ,
we  ||| S:366 E:369 ||| PRP
prefabricated  ||| S:369 E:383 ||| VBP
vascularized  ||| S:383 E:396 ||| JJ
bone  ||| S:396 E:401 ||| NN
grafts  ||| S:401 E:408 ||| VBZ
using  ||| S:408 E:414 ||| VBG
a  ||| S:414 E:416 ||| DT
combination  ||| S:416 E:428 ||| NN
of  ||| S:428 E:431 ||| IN
bone  ||| S:431 E:436 ||| NN
marrow  ||| S:436 E:443 ||| NN
mesenchymal  ||| S:443 E:455 ||| NNS
stem  ||| S:455 E:460 ||| VBP
cells  ||| S:460 E:466 ||| NNS
( ||| S:466 E:467 ||| -LRB-
BMSCs ||| S:467 E:472 ||| NNP
)  ||| S:472 E:474 ||| -RRB-
and  ||| S:474 E:478 ||| CC
vascular  ||| S:478 E:487 ||| JJ
bundles  ||| S:487 E:495 ||| NNS
in  ||| S:495 E:498 ||| IN
a  ||| S:498 E:500 ||| DT
β-tricalcium  ||| S:500 E:513 ||| JJ
phosphate  ||| S:513 E:523 ||| JJ
ceramic  ||| S:523 E:531 ||| NNS
( ||| S:531 E:532 ||| -LRB-
β-TCP ||| S:532 E:537 ||| NNP
) ||| S:537 E:538 ||| -RRB-
.  ||| S:538 E:540 ||| .
We  ||| S:540 E:543 ||| PRP
used  ||| S:543 E:548 ||| VBD
15  ||| S:548 E:551 ||| CD
New  ||| S:551 E:555 ||| NNP
Zealand  ||| S:555 E:563 ||| NNP
White  ||| S:563 E:569 ||| NNP
rabbits  ||| S:569 E:577 ||| NN
as  ||| S:577 E:580 ||| IN
our  ||| S:580 E:584 ||| PRP$
experimental  ||| S:584 E:597 ||| JJ
animals ||| S:597 E:604 ||| NNS
.  ||| S:604 E:606 ||| .
Single  ||| S:606 E:613 ||| JJ
photon-emission  ||| S:613 E:629 ||| JJ
computed  ||| S:629 E:638 ||| JJ
tomography  ||| S:638 E:649 ||| NN
and  ||| S:649 E:653 ||| CC
histologic  ||| S:653 E:664 ||| JJ
analyses  ||| S:664 E:673 ||| NNS
were  ||| S:673 E:678 ||| VBD
used  ||| S:678 E:683 ||| VBN
to  ||| S:683 E:686 ||| TO
evaluate  ||| S:686 E:695 ||| VB
angiogenesis  ||| S:695 E:708 ||| NNS
and  ||| S:708 E:712 ||| CC
new  ||| S:712 E:716 ||| JJ
bone  ||| S:716 E:721 ||| NN
formation  ||| S:721 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
the  ||| S:734 E:738 ||| DT
bone  ||| S:738 E:743 ||| NN
grafts ||| S:743 E:749 ||| NN
.  ||| S:749 E:751 ||| .
The  ||| S:751 E:755 ||| DT
results  ||| S:755 E:763 ||| NNS
showed  ||| S:763 E:770 ||| VBD
that  ||| S:770 E:775 ||| DT
axial  ||| S:775 E:781 ||| JJ
vessels  ||| S:781 E:789 ||| NNS
not  ||| S:789 E:793 ||| RB
only  ||| S:793 E:798 ||| RB
promoted  ||| S:798 E:807 ||| VBN
angiogenesis  ||| S:807 E:820 ||| VBN
of  ||| S:820 E:823 ||| IN
the  ||| S:823 E:827 ||| DT
bone  ||| S:827 E:832 ||| NN
grafts ||| S:832 E:838 ||| NN
,  ||| S:838 E:840 ||| ,
but  ||| S:840 E:844 ||| CC
also  ||| S:844 E:849 ||| RB
enhanced  ||| S:849 E:858 ||| VBN
new  ||| S:858 E:862 ||| JJ
bone  ||| S:862 E:867 ||| NN
formation ||| S:867 E:876 ||| NN
.  ||| S:876 E:878 ||| .
These  ||| S:878 E:884 ||| DT
findings  ||| S:884 E:893 ||| NNS
suggested  ||| S:893 E:903 ||| VBD
that  ||| S:903 E:908 ||| IN
the  ||| S:908 E:912 ||| DT
insertion  ||| S:912 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
blood  ||| S:925 E:931 ||| NN
vessels  ||| S:931 E:939 ||| NNS
into  ||| S:939 E:944 ||| IN
tissue-engineered  ||| S:944 E:962 ||| JJ
bone  ||| S:962 E:967 ||| NN
grafts  ||| S:967 E:974 ||| NNS
was  ||| S:974 E:978 ||| VBD
an  ||| S:978 E:981 ||| DT
effective  ||| S:981 E:991 ||| JJ
strategy  ||| S:991 E:1000 ||| NN
for  ||| S:1000 E:1004 ||| IN
enhancing  ||| S:1004 E:1014 ||| VBG
angiogenesis  ||| S:1014 E:1027 ||| NNS
and  ||| S:1027 E:1031 ||| CC
bone  ||| S:1031 E:1036 ||| NN
formation  ||| S:1036 E:1046 ||| NN
and  ||| S:1046 E:1050 ||| CC
had  ||| S:1050 E:1054 ||| VBD
potential  ||| S:1054 E:1064 ||| JJ
significance  ||| S:1064 E:1077 ||| NN
for  ||| S:1077 E:1081 ||| IN
clinical  ||| S:1081 E:1090 ||| JJ
applications ||| S:1090 E:1102 ||| NNS
.  ||| S:1102 E:1104 ||| .
